江苏省海安县2004-2011年女性乳腺癌流行趋势分析

目的：研究海安县2004-2011年女性乳腺癌的发病率、死亡率及流行趋势。方法：根据海安县2004-2011年肿瘤登记报告数据库及人口资料,进行女性乳腺癌发病率、死亡率、累积率和截缩率分析,采用年变化率（annualpercentchange,APC）模型分析各种率的时间变化趋势。结果：海安县2004-2011年女性乳腺癌粗发病率、中国标化率、世界标化率分别为17．54／10万女性人口（以下发病或死亡率单位如此同,将其省略）、11．06／10^5和10．06／10^5;35～64岁截缩世标发病率和0h70岁累积发病率分别为31．61／10^5和1．06％,居女性恶性肿瘤全部发病病例的第5位。女性乳腺癌粗发病率、中国标化率和世界标化率APC分别为10．53％、7．40％和7．68％,其中粗发病率和世界标化率呈显著上升趋势,P值均do．01;中国标化率呈上升趋势,P〈0．05。女性乳腺癌粗死亡率、中国标化率和世界标化率分别为7,02／10^5、4．43／10^5和4．09／10^5;35～64岁截缩世标死亡率和0～70岁累积死亡率分别为9．59／10^5和0．45％。居女性恶性肿瘤全部死亡病例的第6位。女性乳腺癌粗死亡率、中国标化率和世界标化率APC分别为2．62％、1．83％和1．50％,死亡趋势相对稳定,P值均〉0．05。结论：海安县2004-2011年女性乳腺癌发病率增长趋势明显,死亡率变化趋势相对稳定。     

新疆石河子市2010~2011年女性乳腺癌发病和死亡流行特征

[目的]了解2010~2011年石河子市女性乳腺癌发病与死亡流行特征,为乳腺癌的预防控制提供科学依据。[方法]根据石河子市肿瘤登记处2010~2011年女性乳腺癌发病及死亡资料,统计和分析粗发病率、粗死亡率、年龄别发病率、年龄别死亡率、中标率、世标率指标。[结果 ]2010~2011年石河子市女性乳腺癌新发病例209例,死亡病例64例。乳腺癌发病率为36.61/10万,中标率为19.11/10万,世标率为24.35/10万。乳腺癌死亡率为11.21/10万,中标率为5.72/10万,世标率为7.43/10万。石河子市女性乳腺癌发病从35岁开始,发病率最高峰为50~岁年龄组,死亡率最高峰为60~岁年龄组。[结论 ]石河子市女性乳腺癌死亡率较高,应加强35~54岁女性乳腺癌筛查,有效降低石河子市乳腺癌流行水平。     

2010~2017年新疆石河子市女性乳腺癌流行趋势分析

摘 要：［目的］ 分析新疆石河子市2010～2017年女性乳腺癌发病与死亡流行趋势。［方法］ 根据石河子市2010～2017年肿瘤登记资料,计算女性乳腺癌发病率、死亡率及其标化率,并采用年度变化百分比(APC)模型分析其时间和年龄趋势。［结果］ 2010～2017年石河子市女性乳腺癌发病1221例,发病率为52.95/10万,中标率40.58/10万,世标率33.59/10万;死亡478例,死亡率为20.73/10万,中标率15.58/10万,世标率12.92/10万。女性乳腺癌发病率从2010年的27.41/10万上升到2017年的44.17/10万,增加了61.15%,APC为10.00%(95%CI：4.93%～26.96%,P>0.05);死亡率从2010年的11.60/10万上升到2017年的30.45/10万,增加了162.50%,APC为14.56%(95%CI：0.14%～31.06%,P<0.05)。乳腺癌50～54岁发病率和65～69岁死亡率上升有统计学意义,APC分别为19.46%和12.58%。［结论］ 2010～2017年石河子女性乳腺癌发病、死亡水平增长明显,且发病和死亡人群年轻化,应加强乳腺癌的早诊早治,尤其是中年女性乳腺癌防控工作亟待加强。     

浙江省肿瘤登记地区2000～2009年女性乳腺癌流行趋势

[目的]了解浙江省登记地区女性乳腺癌的发病和死亡的变化趋势。[方法]根据浙江省6个肿瘤登记处上报的数据,计算并分析浙江省肿瘤登记地区女性乳腺癌的发病率和死亡率等指标。2000~2009年女性乳腺癌发病率和死亡率变化趋势釆用年度变化百分比（APC）估计。[结果]浙江省肿瘤登记地区女性乳腺癌发病率为39.24/10万,构成比16.59%,居女性恶性肿瘤发病的第1位。2000~2009年女性乳腺癌发病率呈上升趋势,APC为5.36%（95%CI：2.88~7.91）。浙江省肿瘤登记地区女性乳腺癌的死亡率为6.42/10万,构成比5.72%,居女性恶性肿瘤死亡的第5位。2000~2009年死亡率无统计学意义的变化,APC为1.42%（95%CI：-0.24~3.10）。[结论]浙江省肿瘤登记地区女性乳腺癌发病率和死亡率低于全国平均水平,但发病率增长趋势比较明显,应该进一步加强乳腺癌的防治。     

湖北省麻城市2011～2016年宫颈癌发病和死亡趋势分析

摘 要：［目的］ 分析2011～2016年湖北省麻城市宫颈癌发病及死亡趋势。［方法］ 根据麻城市肿瘤登记处收集的2011～2016年宫颈癌发病数据和相应年份的人口资料,计算宫颈癌发病（死亡）粗率以及中国人口和世界人口标化（简称中标率和世标率）发病（死亡）率,利用SAS9.3软件进行Cochran-Armitage（CA）趋势分析。［结果］ 2011～2016年麻城市宫颈癌发病粗率为15.59/10万,中标率为11.80/10万,世标率11.74/10万。2011~2016年宫颈癌发病粗率CA趋势分析无统计学意义（Z=-1.46,P=0.14）。宫颈癌死亡粗率5.47/10万,中标率为4.15/10万,世标率4.12/10万,麻城市2011～2016年宫颈癌死亡粗率CA趋势检验分析无统计学意义（Z =-1.73,P=0.08）。死亡/发病比为0.35。［结论］ 麻城市2011～2016年宫颈癌发病率和死亡率历年有所波动,未发现明显变化趋势,但死亡/发病比较高,需进一步做好宫颈癌防治工作。     

2002-2015年上海市金山区女性乳腺癌发病和死亡趋势分析

[目的]分析2002-2015年上海市金山区女性乳腺癌发病与死亡情况.[方法]根据上海市肿瘤登记系统收集的2002-2015年金山区女性乳腺癌资料及区公安局提供的人口资料,计算粗发病率、死亡率及其标化率、年龄别率和年度变化百分比(APC)等指标.[结果]2002-2015年共报告女性乳腺癌发病1351例,死亡317例....     

济南市城乡女性乳腺癌2012-2015年发病和死亡分析

目的 乳腺癌是女性最常见的恶性肿瘤.为了解济南市乳腺癌发病和死亡情况,对济南市2012-2015年女性乳腺癌发病和死亡现状进行了分析,为开展乳腺癌干预措施和确定乳腺癌研究方向提供依据.方法 利用济南市肿瘤监测系统提供的2012-2015年女性乳腺癌发病、死亡资料以及相应的人口资料,计算城区与农村地区年粗发病率/死亡率、世标率、年度变化率、发病年龄、绝经前/后患者比例、年龄别发病率/死亡率和城区与农村地区乳腺癌发病率、死亡率之比,采用Excel 2007、SPSS 16.0软件进行统计学分析.结果 2012年济南市城区和农村地区女性乳腺癌发病年龄分别为(54.40±12.40)和(52.02±12.48)岁,2015年分别为(55.34±12.14)和(53.15±12.10)岁,与2012年相比2015年城区和农村地区平均发病年龄分别增加了0.94和1.13岁;＜50岁年龄组乳腺癌患者的比例城区由2012年的38.20％降至2015年的33％,农村地区由2012年的47.10％降至2015年的43.65％.2012-2015年济南市城区女性乳腺癌年均发病率为52.77/10万,年均死亡率为9.76/10万,农村地区年均发病率为44.77/10万,年均死亡率为10.78/10万.2012-2015年济南市城、乡地区女性乳腺癌患者发病率比值30～＜55岁年龄组在0.97～1.08,25～＜30岁年龄组以及≥55岁年龄组在1.20～1.55,合计比值为1.24.2012-2015年济南市城乡地区女性乳腺癌发病率高峰分别在55～＜60岁(121.21/10万)和50～＜55岁(94.73/10万),≥60岁随着年龄增长发病率逐渐下降.死亡率高峰城乡地区分别在65～＜70岁(22.34/10万)和50～＜55岁(25.04/10万),济南市城区≥60岁随着年龄增长死亡率未见明显下降,而农村地区≥60岁随着年龄增长死亡率有所下降.结论 济南市女性乳腺癌年均发病率城区高于农村地区,而死亡率农村地区高于城区;发病、死亡高峰年龄城区均晚于农村地区.应采取相应的提早干预措施对肿瘤早发现、早治疗以改善预后.     

兰州市2010年女性乳腺癌发病及流行趋势分析

[目的]了解2010年兰州市女性乳腺癌的发病状况及变化趋势,为乳腺癌的防治研究提供科学依据。[方法]根据甘肃省肿瘤登记处2010年登记的恶性肿瘤发病病例资料,统计和分析2010年女性乳腺癌发病情况。利用Joinpoint模型分析兰州市女性乳腺癌在2005~2010年发病趋势。[结果]兰州市2010年女性乳腺癌的发病率为25.14/10万,居全部恶性肿瘤发病顺位第1位。中标率18.99/10万,世标率23.58/10万,低于世界、亚洲、发达国家及发展中国家平均发病水平,接近中国平均发病水平。2005~2010年女性乳腺癌发病率呈直线上升趋势。[结论]乳腺癌是威胁兰州市女性健康的最主要恶性肿瘤,且发病率呈增高趋势,应着力加强防治研究。     

上海市闵行区女性乳腺癌发病流行趋势分析

[目的]描述上海市闵行区乳腺癌的发病流行现况,分析乳腺癌的时间趋势,为预防控制工作提供依据。[方法]采用上海市肿瘤登记报告和随访管理系统收集的乳腺癌发病资料,以及年度变化百分比对上海市闵行区1993～2006年女性乳腺癌发病的时间趋势进行分析。[结果]2002～2006年,闵行全区共新诊断乳腺癌1030例,总发病粗率为54.77/10万,世标率为32.71/10万。乳腺癌是闵行区女性发病第一位的恶性肿瘤,占所有恶性肿瘤发病的17.38%。2002～2006年新发乳腺癌病例早期率为23.20%。乳腺癌发病率随年龄增加逐渐增加,35岁后进入加速增长期,50～55岁为发病高峰,随后发病率逐渐下降。1993～2006年闵行区乳腺癌粗发病率、标化发病率分别以年均变化率（APC）7.53%、3.56%的速度快速上升。城区女性乳腺癌发病呈快速上升趋势,而农村女性则上升不明显。[结论]闵行区女性乳腺癌发病处于发达国家和发展中国家水平之间,乳腺癌早发现工作亟待加强,35岁以上女性乳腺癌早发现工作作为重点。     

乳腺癌当前流行趋势分析

乳腺癌自２０世纪７０年代末开始,其发病数一直位居女性肿瘤首位并且全球每年约以２％的速度递增。据有关资料分析,按此增长速度预计到２０１０年,全球乳腺癌的年新发病例数将有可能达到１４０万左右。本文搜集整理了近２０年乳腺癌的发病资料［１－４］,并根据最近有关乳腺癌的统计学报告［５,６］,拟就全球及我国乳腺癌当前流行趋势作一简要分析。１乳腺癌的发病趋势１.１全球乳腺癌发病现状 １９７５年全球乳腺癌年新病例数为５４．１２万,而到１９９０年则增至 ７９. ４８万（见表 １）, ２０年内发病数增加了 ４７％,同朗相比…     

Ovary cancer incidence and mortality in China, 2011

Objective

To evaluate and analyze ovary cancer incidence and mortality in China in 2011 using ovary cancer data from population-based cancer registration in China, and to provide scientific information for its control and prevention.

Methods

Invasive cases of ovary cancer were extracted and analyzed from the overall Chinese cancer database in 2011, which were based on data from 177 population-based cancer registries distributing in 28 provinces. The crude, standardized, and truncated incidences and mortalities et al. were calculated and new and deaths cases from ovary cancer throughout China and in different regions in 2011 were estimated using Chinese practical population.

Results

The estimates of new ovary cancer cases and deaths were 45,223 and 18,430, respectively, in China in 2011. The crude incidence rate, age-standardized rate by Chinese standard population (ASR-C) and age-standardized rate by world standard population (ASR-W) incidence were 6.89/100,000, 5.35/100,000 and 5.08/100,000, respectively; the crude, ASR-C and ASR-W mortalities were 2.81/100,000, 2.01/100,000 and 1.99/100,000, respectively. The incidence and mortality in urban areas were higher than those in rural areas. The age-specific incidence and mortality increased rapidly from age 35-39 and peaked at age 60-64 or 75-79 years. After age 45 or 55, the age-specific incidence and death rates in urban were much higher than those in rural areas.

Conclusions

Compared with GLOBOCAN 2012 data, the ovary cancer incidence in China in 2011 was at middle level, but its mortality was at low level worldwide.     

Impressive time-related influence of the Dutch screening programme on breast cancer incidence and mortality, 1975-2006

The aim of this study was to assess changes in the trends in breast cancer mortality and incidence from 1975 to 2006 among Dutch women, in relation to the implementation of the national breast cancer screening programme. Screening started in 1989 for women aged 50-69 and was extended to women aged 70-75 years in 1998 (attendance rate approximately >80%). A joinpoint Poisson regression analysis was used to identify significant changes in rates over time. Breast cancer mortality rates increased until 1994 (age group 35-84), but thereafter showed a marked decline of 2.3-2.8% per annum for the age groups 55-64 and 65-74 years, respectively. For the age group of 75-84 years, a decrease started in the year 2001. In women aged 45-54, an early decline in breast cancer mortality rates was noted (1971-1980), which is ongoing from 1992. For all ages, breast cancer incidence rates showed an increase between 1989 and 1993, mainly caused by the age group 50-69, and thereafter, a moderate increase caused by age group 70-74 years. This increase can partly be explained by the introduction of screening. The results indicate an impressive decrease in breast cancer mortality in the age group invited for breast cancer screening, starting to show quite soon after implementation.     

Recent trends in breast cancer incidence,mortality, and mammography

Summary The recent trends in mammography, and in breast cancer incidence and mortality, demonstrate the impact of an effective cancer control effort. The number of women over age 40 years who have ever had mammography has increased over 200% since 1980. Concomitantly, breast cancer incidence has increased about 32%, with nearly all of the increase in early stage disease. Analytic studies of these changes have demonstrated persuasively that the vast majority of this increase is temporary and is attributable to the lead-time afforded by mammography. As a result of this early detection and treatment of breast cancer, mortality has begun to decline in 1991–92. Although the search for practical preventive measures should continue, the benefits of early detection can be realized now. Further research is needed to define age groups most appropriately screened and the optimum intervals for screening.     

Pancreatic cancer incidence and mortality patterns in China, 2011

Objective

The National Central Cancer Registry (NCCR) collected population-based cancer registration data in 2011 from all cancer registries in China. The incidence and mortality rates for pancreatic cancer were compiled and pancreatic cancer incident new cases and deaths were estimated.

Methods

A total of 234 cancer registries submitted cancer data to NCCR. Data from 177 cancer registries were qualified and compiled for cancer statistics in 2011. Pancreatic cancer cases were extracted and analyzed from the national database. The pooled data were stratified by area (urban/rural), gender and age group (0, 1-4, 5-9, 10-14…85+). Pancreatic cancer incident cases and deaths were estimated using age-specific rates and national population in 2010. The national census in 2000 and Segi’s population were used for age-standardized rates.

Results

All 177 cancer registries (77 in urban and 100 in rural areas) covered 175,310,169 populations (98,341,507 in urban and 76,968,662 in rural areas). The morphology verified pancreatic cancer cases (MV%) accounting for 40.52% and 4.33% of pancreatic cancer incident cases were identified through death certifications only (DCO%) with mortality to incidence ratio (M/I) of 0.91. The estimated number of newly diagnosed pancreatic cancer cases and deaths were 80,344 and 72,723 in 2011, respectively. The crude incidence rate was 5.96/100,000 (males 6.57/100,000, females 5.32/100,000). The age-standardized incidence rates by Chinese standard population (ASIRC) and by world standard population (ASIRW) were 4.27/100,000 and 4.23/100,000 respectively, ranking 10^th among all cancers. Pancreatic cancer incidence rate and ASIRC were 7.03/100,000 and 4.94/100,000 in urban areas whereas they were 4.84/100,000 and 3.56/100,000 in rural areas. The incidence rate of pancreatic cancer of 33 cancer registries increased from 3.24/100,000 in 2003 to 3.59/100,000 in 2011 with an annual percentage change (APC) of 1.44. The pancreatic cancer mortality rate was 5.40/100,000 (males 5.88/100,000, females 4.89/100,000), ranking 6^th among all cancers. The age-standardized mortality rates by Chinese standard population (ASMRC) and by world standard population (ASMRW) were 3.81/100 000 and 3.79/100 000. The pancreatic cancer mortality and ASMRC were 6.47/100,000 and 4.48/100,000 in urban areas, and 4.27/100,000 and 3.08/100,000 in rural areas, respectively. The mortality rates of pancreatic cancer showed an approximately 1.14-fold increase, from 2.85/100,000 in 2003 to 3.26/100,000 in 2011, with an APC of 1.68.

Conclusions

The burden of pancreatic cancer is increasing in China. Identification of high-risk population and adequate treatment and prevention are important.     

淮安市女性乳腺癌发病和死亡分析

目的分析淮安市2009-2011年女性乳腺癌发病与死亡的流行特征,为乳腺癌的防治工作提供依据。方法利用淮安市恶性肿瘤登记报告工作收集淮安市2009-2011年女性乳腺癌的发病和死亡数据,分年龄、地区(城市和农村)分析淮安市乳腺癌流行病学特征。结果淮安地区2009-2011年乳腺癌发病共1 225例,粗发病率16.01/10万,城市20.22/10万,农村11.77/10万;标化发病率为13.19/10万,城市16.33/10万,农村10.03/10万。乳腺癌死亡共415例,粗死亡率为5.43/10万,城市6.66/10/10万,农村4.18/10万;标化死亡率为4.23/10万,城市5.15/10万,农村3.25/10万。发病死亡均为城市高于农村。2009-2011年发病(χ2=94.57,P<0.001)和死亡(χ2=8.66,P<0.001)均呈现逐年增加趋势。分年龄组分析,乳腺癌发病呈单峰分布,高峰在55~岁年龄组;死亡则呈双峰分布,高峰分别在55~岁年龄组及80~岁年龄组,最高峰在55~岁年龄组。结论淮安区城市乳腺癌发病和死亡均高于农村,并呈现逐年上升趋势,发病和死亡最高峰均在55~岁年龄组,严重威胁淮安地区中老年女性的生命健康。     

2010-2018年重庆市恶性肿瘤发病死亡趋势分析

目的:分析重庆市2010-2018年恶性肿瘤发病死亡变化趋势。方法:收集整理2010-2018年重庆市肿瘤登记点恶性肿瘤发病死亡资料,采用SPSS 25.0分析恶性肿瘤发病率、中国人口标化发病率、世界人口标化发病率、年龄别发病率、死亡率、中国人口标化死亡率、世界人口标化死亡率、年龄别死亡率等。男性与女性、城市与农村发病率、死亡率的比较采用χ2检验,趋势变化采用年度变化百分比（APC）,对APC的检验采用t检验。结果:重庆市恶性肿瘤发病率、中标率与世标率分别由2010年的200.08/10万、147.03/10万、162.53/10万上升至2018年的289.63/10万、195.85/10万、209.74/10万,APC分别为5.02%(4.39%～5.65%)、4.29%(3.77%～4.81%)、3.87%(3.36%～4.39%),变化趋势均有统计学意义（P＜0.01）。恶性肿瘤发病率历年均是男性高于女性（P＜0.05）。2011年与2015年城市与农村地区恶性肿瘤发病率差异无统计学意义（P＞0.05）,其它年份恶性肿瘤发病率均是城市高于农村,差异有统计学意义（P＜0.05）。男性与女性、城市与农村恶性肿瘤发病率均明显上升（P＜0.05）。2010年重庆市恶性肿瘤死亡率、中标死亡率与世标死亡率分别为152.10/10万、103.49/10万、117.91/10万,2018年死亡率、中标死亡率与世标死亡率分别为184.77/10万、110.87/10万、125.53/10万,死亡率以年均3.15%(2.33%～3.98%)上升（t=4.03,P=0.005）。恶性肿瘤死亡率历年均是男性高于女性。2010-2018年男性与女性恶性肿瘤死亡率分别以3.46%(2.63%~4.29%)与2.63%(1.92%～3.36%)上升（t=4.36,P=0.003;t=3.43,P=0.011）。2010-2018年城市地区恶性肿瘤死亡率变化趋势差异无统计学意义（P＞0.05）。2010-2018年农村地区恶性肿瘤死亡率以年均3.05%(2.33%～3.77%)上升（t=4.03,P=0.005）。结论:重庆市恶性肿瘤发病率与死亡率呈快速上升的趋势,应针对危险因素进行干预和普及早诊早治,降低恶性肿瘤的发病率与死亡率。     

Incidence and mortality of female breast cancer in the AsiaPacific region

Objective： To provide an overview of the incidence and mortality of female breast cancer for countries in the Asia-Pacific region.Methods： Statistical information about breast cancer was obtained from publicly available cancer registry and mortality databases（such as GLOBOCAN）, and supplemented with data requested from individual cancer registries. Rates were directly age-standardised to the Segi World Standard population and trends were analysed using joinpoint models.Results： Breast cancer was the most common type of cancer among females in the region, accounting for 18% of all cases in 2012, and was the fourth most common cause of cancer-related deaths（9%）. Although incidence rates remain much higher in New Zealand and Australia, rapid rises in recent years were observed in several Asian countries. Large increases in breast cancer mortality rates also occurred in many areas, particularly Malaysia and Thailand, in contrast to stabilising trends in Hong Kong and Singapore, while decreases have been recorded in Australia and New Zealand. Mortality trends tended to be more favourable for women aged under 50 compared to those who were 50 years or older. Conclusion： It is anticipated that incidence rates of breast cancer in developing countries throughout the Asia-Pacific region will continue to increase. Early detection and access to optimal treatment are the keys to reducing breast cancerrelated mortality, but cultural and economic obstacles persist. Consequently, the challenge is to customise breast cancer control initiatives to the particular needs of each country to ensure the best possible outcomes.     

Time trends of breast cancer survival in Europe in relation to incidence and mortality

Increasing breast cancer survival, observed in most western countries, is not easily interpreted: it could be due to better treatment, more effective treatment due to earlier diagnosis or simply lead-time bias. Increased diagnostic activity (e.g., screening) can inflate both incidence and survival. To understand interrelations between incidence, mortality and survival trends and their consequences, we analyzed survival trends in relation to mortality and incidence. Starting with observed survival from EUROCARE, mortality from WHO and using the MIAMOD method, we estimated breast cancer incidence trends from 1970 to 2005 in 10 European countries. To smooth out peaks in incidence and survival due to early diagnosis activity, survival trends were assumed similar to those observed by EUROCARE in 1983-1994. The following patterns emerged: (1) increasing survival with increasing incidence and declining or stable mortality (Sweden, Finland); (2) slight survival increase, marked incidence increase and slight mortality decrease (Denmark, the Netherlands and France); (3) increasing survival, marked decrease in mortality and tendency to incidence stabilization (UK); (4) marked survival increase, steady or decreasing mortality and moderate increases in incidence (Spain, Italy); (5) stable survival, increasing incidence and mortality (Estonia). In most countries survival increased, indicating a real advantage for patients when accompanied by decreasing or stable mortality, and attributable to improved cancer care (Sweden, UK, France, Italy and Spain). In Finland (with high survival), the Netherlands and Denmark, increasing mortality and incidence indicate increasing breast cancer risk, probably related to life-style factors. In Estonia, low and stable survival in the context of increasing incidence and mortality suggests inadequate care.     

2015年重庆市城乡女性乳腺癌发病及死亡现状分析

目的:了解重庆市女性乳腺癌发病与死亡现状,为开展乳腺癌防治提供建议.方法:收集整理2015年重庆市11个肿瘤登记点报告的乳腺癌(ICD-10编码为C50).采用SPSS 19.0统计分析发病率、死亡率、标化发病率、标化死亡率、构成比、顺位.不同地区间乳腺癌发病率与死亡率的比较采用χ2检验,年龄别发病率与死亡率趋势分析采用趋势χ2检验.结果:2015年11个肿瘤登记点女性乳腺癌粗发病率为31.48/10万,城市发病率(42.07/10万)高于农村(26.32/10万),差异有统计学意义(P=0.002),乳腺癌标化发病率为24.20/10万,在女性恶性肿瘤中顺位居第2位,占6.00%.女性乳腺癌粗死亡率为7.33/10万,城市(8.77/10万)与农村乳腺癌死亡率(6.62/10万)差异无统计学意义(P=0.099),乳腺癌标化死亡率为4.96/10万,在恶性肿瘤死亡顺位中居第6位,占2.10%.女性乳腺癌发病率25岁前低于5/10万,25岁后快速上升,50岁~年龄组达到高峰,随后下降.女性乳腺癌死亡率在40岁前低于5/10万,40岁后呈上升趋势,80岁~年龄组达到高峰.女性乳腺癌截缩发病率为56.01/10万,城市(67.91/10万)高于农村(50.55/10万),差异有统计学意义(P=0.001).截缩死亡率为10.75/10万,乳腺癌截缩死亡率城市(11.96/10万)与农村(10.42/10万)比较差异无统计学意义(P=0.136).发病累积危险度为2.27%,城市(3.07%)高于农村(1.93%),差异有统计学意义(P=0.039).死亡累积危险度为0.51%.结论:重庆市女性乳腺癌发病率与死亡率较高,应针对城乡女性乳腺癌发病死亡特点开展三级预防.